首页> 外文会议>International Symposium on VIP, PACAP, and Related Peptides >VIP and PACAP Receptor Pharmacology:A Comparison of Intracellular Signaling Pathways
【24h】

VIP and PACAP Receptor Pharmacology:A Comparison of Intracellular Signaling Pathways

机译:VIP和PACAP受体药理学:细胞内信号通路的比较

获取原文

摘要

VIP/PACAP receptor activation stimulates the production of [cAMP]_i and [Ca~(2+)]i by coupling to independent G-protein sub-units, although agonist potencies for the different transduction pathways appear to differ. Using CHO-Kl cells stably expressing the human VIP/PACAP receptors (hVPAC_1R, hVPAC_2R, and hPAC_1R), functional assays ([cAMP]i and [Ca~(2+)]i) were established and the receptor pharmacology was characterized with five peptide agonists (VIP, PACAP27, PACAP-38, [Ala~(11,22.28)]VIP, and R3P65). The rank order of potency (ROP) was consistent between assays for the individual receptor subtypes, however, higher agonist concentrations (~100-fold) were required for stimulating [Ca~(2+)]i when compared to [cAMP]i.
机译:VIP / PACAP受体激活刺激通过与独立的G蛋白子单元偶联的[阵营] _I和[CA〜(2 +)]的产生,尽管不同转导途径的激动剂效力似乎不同。使用稳定表达人VIP / PACAP受体(HVPAC_1R,HVPAC_2R和HPAC_1R)的CHO-KL细胞,建立了功能测定([阵营] I和[CA〜(2 +)] I),并将受体药理学表征为五个肽激动剂(VIP,PACAP27,PACAP-38,[ALA〜(11,22.28)] VIP和R3P65)。效力(ROP)的等级顺序在各个受体亚型的测定之间一致,然而,与[阵营] I相比,刺激[Ca〜(2 +)]时需要更高的激动剂浓度(〜100倍)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号